Valuation: ChitogenX Inc.

Market Cap 831K 592K 531K 491K 445K 56.41M 841K 5.87M 2.34M 29.52M 2.22M 2.18M 93.71M P/E 2023
-2.01x
P/E 2024 -3.99x
Enterprise Value 4.67M 3.33M 2.99M 2.76M 2.5M 317M 4.73M 33.01M 13.15M 166M 12.49M 12.23M 527M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
100%
Yield 2023 *
-
Yield 2024 -
3 years 0
Extreme 0
0.12
5 years 0
Extreme 0
0.6
10 years 0
Extreme 0
1
Manager TitleAgeSince
Chief Executive Officer 65 28/02/2024
Director of Finance/CFO 62 18/09/2018
Chief Tech/Sci/R&D Officer 68 -
Director TitleAgeSince
Chairman 67 06/03/2019
Chairman 65 26/07/2016
Chairman 65 -
Date Insider Type Main position Quantity % Market Cap. Importance
19/11/24 Buy

Chief Financial Officer

710,000 0.8541%
17/07/24 Option

Chief Executive Officer

544,400 0.6549%
17/07/24 Option

General Counsel

100,000 0.1203%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-93.75% 296K
+0.34%-3.03%+37.45%+61.06% 64.14B
+0.80%+2.48%+12.03%+83.54% 55.53B
+1.22%+1.50%+12.73%+104.69% 53.03B
-0.86%-0.67%+26.91%+56.05% 45.99B
-0.14%-2.24%+18.70%+100.27% 42.45B
+0.48%+1.04%+226.85%+933.46% 40.45B
+0.64%-3.95%+11.15%+45.57% 32.25B
-1.29%+43.48%+104.84%+91.26% 34.47B
-2.72%-0.44%+23.18%-10.77% 24.23B
Average -0.15%+3.47%+47.38%+137.14% 39.25B
Weighted average by Cap. +0.04%+3.16%+49.65%+160.63%

Financials

2023 2024
Net sales - -
Net income -6.23M -4.44M -3.98M -3.68M -3.33M -423M -6.31M -44.02M -17.53M -221M -16.66M -16.31M -702M -1.55M -1.11M -993K -918K -832K -105M -1.57M -10.98M -4.37M -55.18M -4.15M -4.07M -175M
Net Debt 6.21M 4.42M 3.97M 3.67M 3.32M 421M 6.28M 43.85M 17.47M 220M 16.59M 16.24M 700M 3.84M 2.74M 2.45M 2.27M 2.06M 261M 3.89M 27.13M 10.81M 136M 10.27M 10.05M 433M
Projected Income Statement - Annual - ChitogenX Inc.
Logo ChitogenX Inc.
ChitogenX Inc. is a Canada-based clinical-stage regenerative medicine company. The Company is engaged in the development of therapeutic tissue repair technologies to improve tissue healing. The Company is committed to the clinical development of its proprietary RESTORE technology platform, a muco-adhesive CHITOSAN based biopolymer matrix, specifically designed to deliver biologics such as platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC), to enhance healing in various musculoskeletal conditions. Ortho-R, its lead Chitosan-PRP hybrid biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, and cartilage such as the meniscus. Its other formulations are being developed to leverage the technology's performance characteristics, such as tissue adhesion, pliability, and ability to deliver biologics or therapeutics to various tissues damaged by trauma or disease.
Employees
-

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - ChitogenX Inc.
  1. Stock Market
  2. Stocks
  3. CHGX Stock